Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;24(12):959-967.
doi: 10.1007/s11883-022-01071-1. Epub 2022 Nov 11.

ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis

Farzahna Mohamed  1 , Brett S Mansfield  1 , Frederick J Raal  2
Affiliations
Review

ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis

Farzahna Mohamed et al. Curr Atheroscler Rep. 2022 Dec.

Abstract

Purpose of review: Elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride-rich lipoproteins (TRLs) or remnants are important risk factors for the development of atherosclerotic cardiovascular disease (ASCVD). The ongoing challenge of not being able to achieve recommended LDL-C targets despite maximally tolerated lipid-lowering therapy (LLT) has led to the development of novel therapeutic agents including angiopoietin-like 3 (ANGPTL3) inhibitors.

Recent findings: ANGPTL3 is a glycoprotein produced by the liver that inhibits lipoprotein lipase and endothelial lipase. Data from genetic and clinical studies have shown that a lower ANGPTL3 level is associated with lower plasma LDL-C, triglyceride (TG), and other lipoproteins. Pharmacological inactivation of ANGPTL3 with the monoclonal antibody, evinacumab, results in a 50% reduction in LDL-C, even in patients with homozygous familial hypercholesterolemia (HoFH). The safe and effective targeted delivery of nucleic acid-based therapies will shape the future of the lipid arena. ANGPTL3 is a novel target in lipoprotein metabolism, targeting not only LDL-C via an LDL-receptor (LDLR) independent mechanism but also TRLs and carries a significant promise for further ASCVD risk reduction.

Keywords: ANGPTL3; Atherosclerosis; Endothelial lipase; LDL-C; Lipoprotein lipase; Residual cardiovascular risk; Triglycerides.

PubMed Disclaimer

Conflict of interest statement

FJR has received research grants, honoraria, or consulting fees for professional input and/or delivered lectures from Sanofi-Aventis, Regeneron, Amgen, Novartis, and LIB Therapeutics. FM and BSM have no disclosures.

Figures

Fig. 1
Fig. 1
Strategies to reduce residual CV risk have recently been focused on lowering TG levels. ANGPTL3 inhibitors have the benefit of reducing both LDL-C and TGs, and are thus indicated in both familial and mixed hypercholesterolemia, whereby target LDL-C is not achieved despite optimal LLT. Both ANGPTL3 and APOC inhibition are equally effective in reducing TG levels; however, there may be greater efficacy of TG reduction with the APOC-III inhibitors. Inhibition of ANGPTL3 has the benefit of greater LDL-C lowering and would thus be indicated in FH patients and those with mixed dyslipidemia. Adapted by permission from Springer Nature from: Ward NC et al. BioDrugs. 2022;36(2):121–135) [•]. ANGPTL3, angiopoietin-like 3; APOC-III, apolipoprotein C-III; FCS, familial chylomicronemia syndrome; HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; HC, hypercholesterolemia; LLT, lipid-lowering therapy; TG, triglycerides
See this image and copyright information in PMC

References

    1. Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118(4):579–585. doi: 10.1161/CIRCRESAHA.115.306398. - DOI - PMC - PubMed
    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493):1267–78. doi: 10.1016/S0140-6736(05)67394-1. - DOI - PubMed
    1. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemia patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018;103(8):3019–3027. doi: 10.1210/jc.2018-00470. - DOI - PubMed
    1. Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, Vupanorsen Study Investigators et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridemia. Eur Heart J. 2020;41(40):3936–3945. doi: 10.1093/eurheartj/ehaa689. - DOI - PMC - PubMed
    1. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547–563. doi: 10.1161/CIRCRESAHA.115.306249. - DOI - PubMed